Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis.

Brain Research
Getaw Worku HassenForoozan Mokhtarian

Abstract

Axonal injury is the major correlate of permanent disability in neurodegenerative diseases such as multiple sclerosis (MS), especially in secondary-progressive MS which follows relapsing-remitting disease course. Proteolytic enzyme, calpain, is a potential candidate for causing axonal injury. Most current treatment options only target the inflammatory component of MS. Previous work using calpain inhibitor CYLA in our laboratory showed significant reduction in clinical sign, demyelination and tissue calpain content in acute experimental autoimmune encephalomyelitis (EAE). Here we evaluated markers of axonal injury (amyloid precursor protein, Na(v)1.6 channels), neuronal calpain content and the effect of CYLA on axonal protection using histological methods in chronic EAE [myelin oligodendrocyte glycoprotein (MOG)-induced disease model of MS]. Intraperitoneal application of CYLA (2 mg/mouse/day) significantly reduced the clinical signs, tissue calpain content, demyelination and inflammatory infiltration of EAE. Similarly, markers for axonal injury were barely detectable in the treated mice. Thus, this novel drug, which markedly suppresses the disease course, axonal injury and its progression, is a candidate for the treatment of a ...Continue Reading

References

Mar 1, 1979·Journal of Neurochemistry·J E Haley, R W Ledeen
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·E H KooD L Price
Jun 1, 1991·Brain : a Journal of Neurology·D BarnesW I McDonald
May 1, 1973·Journal of Neurochemistry·P Lähdesmäki, S S Oja
Jun 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·R SimanG Lynch
Mar 1, 1995·Brain Research. Brain Research Reviews·J GehrmannG W Kreutzberg
Jan 1, 1995·Critical Reviews in Clinical Laboratory Sciences·R Martin, H F McFarland
Jan 1, 1993·Glia·R B BanatiG W Kreutzberg
Apr 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·K SaitoR A Nixon
Oct 1, 1995·Journal of Neuroscience Research·R V DeshpandeN L Banik
Mar 1, 1997·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·E N Benveniste
Mar 1, 1997·Brain : a Journal of Neurology·B FergusonV H Perry
Jan 29, 1998·The New England Journal of Medicine·B D TrappL Bö
Jul 30, 1999·Journal of Neuroimmunology·B D TrappA Chang
Sep 28, 1999·Current Opinion in Neurology·B D TrappR Rudick
Feb 1, 2003·Journal of the Neurological Sciences·C BjartmarB D Trapp
Apr 15, 2003·Current Neurology and Neuroscience Reports·Kottil W Rammohan
Mar 23, 2004·Current Molecular Medicine·Peter K Stys
May 4, 2004·Annals of Neurology·David A BechtoldKenneth J Smith
May 19, 2004·Proceedings of the National Academy of Sciences of the United States of America·Matthew J CranerStephen G Waxman
Oct 20, 2004·Trends in Pharmacological Sciences·Stephen G WaxmanJoel A Black
Dec 30, 2004·Neurology·Syed A Rizvi, Mark A Agius
Jan 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·A PetzoldG Giovannoni
Apr 27, 2005·Brain Research. Brain Research Reviews·Jerome J A HendriksChristine D Dijkstra
May 19, 2005·Journal of the Neurological Sciences·Peter K Stys
Mar 21, 2006·Acta Neuropathologica·Maria Diaz-SanchezMargaret M Esiri
Sep 30, 2006·Journal of Neuroimmunology·Getaw Worku HassenForoozan Mokhtarian

❮ Previous
Next ❯

Citations

Apr 6, 2013·Neuroscience Bulletin·Andrew N BankstonYue Feng
Aug 21, 2013·CNS Drugs·Amir-Hadi MaghziEmmanuelle Waubant
Aug 16, 2011·Neuroreport·Joel DavidDaniel M Rosenbaum
May 5, 2011·World Journal of Biological Chemistry·Amanda Kathleen Fakira, Stella Elkabes
Mar 19, 2014·Nature Reviews. Neurology·Manuel A FrieseLars Fugger
Mar 1, 2014·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Fan ZhangShu Han
Jun 16, 2011·The International Journal of Neuroscience·Henrik Hasseldam, Flemming Fryd Johansen
Mar 25, 2014·Experimental Neurology·Benjamin SchattlingManuel A Friese
Jun 19, 2010·Progress in Neurobiology·Eilhard MixUwe K Zettl
Feb 4, 2010·Pharmacology & Therapeutics·Anneke Van der WaltTrevor Kilpatrick
Jul 25, 2009·Journal of Neurochemistry·Mary K GuytonNaren L Banik
Aug 28, 2014·Acta Neuropathologica Communications·Jae LeeSteven Petratos
May 19, 2016·Expert Review of Clinical Immunology·Vikram Bhise, Suhayl Dhib-Jalbut
Nov 12, 2016·Nature Reviews. Drug Discovery·Yasuko OnoHiroyuki Sorimachi
Nov 9, 2017·The Journal of Cell Biology·Simon Pan, Jonah R Chan
Apr 24, 2010·Current Opinion in Neurology·Arturo MangasMichel Geffard
Jan 1, 2013·Brain Sciences·Maria PodbielskaEdward L Hogan
Jun 2, 2017·Experimental and Therapeutic Medicine·Weihua LiangLuyan Wang
Aug 17, 2018·BioMed Research International·Ankit TandonRajnish Kumar Chaturvedi
Mar 26, 2021·Frontiers in Cell and Developmental Biology·Greg J DuncanBen Emery

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.